Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
F 9.45 -2.78% -0.27
MESO closed down 2.78 percent on Tuesday, January 19, 2021, on 1.29 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical MESO trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.78%
Multiple of Ten Bearish Other -2.78%
Outside Day Range Expansion -2.78%
Wide Bands Range Expansion -2.78%
Down 3 Days in a Row Weakness -2.78%
Older End-of-Day Signals for MESO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mesoblast Limited Description

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Pharmaceutical Industry Bone Stem Cells Therapeutic Product Proprietary Technology Cardiovascular Disease Hematology Rheumatoid Arthritis Therapeutic Products Heart Failure Spine Vascular Diseases Cardiovascular Diseases Pharmaceutical Industries Transplantation Bone Marrow Diabetic Nephropathy Adult Stem Cell Cell Product Ischemia Back Pain Congestive Heart Failure Host Disease Spinal Fusion Teva Pharmaceutical Industries Graft Versus Host Disease Skeletal Disorders Host Diseases Inflammatory Conditions Mesoblast Regenerative Biomedicine Bone Marrow Transplantation Cardiac Diseases Degenerative Disc Disease Musculoskeletal Disorders

Is MESO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.28
52 Week Low 3.1201
Average Volume 905,496
200-Day Moving Average 12.56
50-Day Moving Average 12.05
20-Day Moving Average 9.13
10-Day Moving Average 9.60
Average True Range 1.00
ADX 26.08
+DI 36.69
-DI 33.83
Chandelier Exit (Long, 3 ATRs ) 14.21
Chandelier Exit (Short, 3 ATRs ) 10.99
Upper Bollinger Band 10.67
Lower Bollinger Band 7.59
Percent B (%b) 0.6
BandWidth 33.74
MACD Line -0.76
MACD Signal Line -0.98
MACD Histogram 0.2161
Fundamentals Value
Market Cap 1.11 Billion
Num Shares 118 Million
EPS -0.91
Price-to-Earnings (P/E) Ratio -10.38
Price-to-Sales 101.32
Price-to-Book 3.30
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.34
Resistance 3 (R3) 10.37 10.12 10.19
Resistance 2 (R2) 10.12 9.89 10.10 10.14
Resistance 1 (R1) 9.78 9.75 9.66 9.75 10.09
Pivot Point 9.53 9.53 9.46 9.51 9.53
Support 1 (S1) 9.19 9.30 9.07 9.16 8.81
Support 2 (S2) 8.94 9.16 8.92 8.76
Support 3 (S3) 8.60 8.94 8.71
Support 4 (S4) 8.57